Biological cost of different mechanisms of colistin resistance and their impact on virulence in acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 518-526

  Beceiro, Alejandro ^a   Moreno, Antonio ^a,b   Fernández, Nathalie ^a   Vallejo, Juán A ^a   Aranda, Jesús ^a,b,c   Adler, Ben ^d   Harper, Marina ^d   Boyce, John D ^d   Bou, Germán ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Servicio de Microbiología   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; LIPID A; PHOSPHOETHANOLAMINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CAENORHABDITIS ELEGANS; CELL VIABILITY; COMPETITIVE ABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACINETOBACTER BAUMANNII; ANIMALS; CELL LINE; COLISTIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; VIRULENCE;

EID: 84891526389     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01597-13     Document Type: Article

References (46)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Wendt C, Dietze B, Dietz E, Rüden H. 1997. Survival of Acinetobacter baumannii on dry surfaces. J. Clin. Microbiol. 35:1394-1397.
3. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939-951. http://dx.doi.org/10.1038/nrmicro1789.
4. Park YK, Lee GH, Baek JY, Chung DR, Peck KR, Song JH, Ko KS. 2010. A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea. Microb. Drug Resist. 16: 143-149. http://dx.doi.org/10.1089/mdr.2009.0088.
5. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25. http://dx.doi.org/10.1016/j.ijantimicag .2004.10.001.
6. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero- Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego- Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118. http://dx.doi.org/10.1086/374337.
7. Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. 2013. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrob. Agents Chemother. 57:592-596. http://dx.doi.org/10.1128/AAC. 01314-12.
8. Mahgoub S, Ahmed J, Glatt AE. 2002. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am. J. Infect. Control 30:386-390. http://dx.doi.org/10.1067/mic.2002.122648.
9. Pristovsek P, Kidric J. 1999. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: An NMR and molecular modeling study. J. Med. Chem. 42:4604-4613. http://dx.doi.org/10.1021 /jm991031b.
10. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67:1607-1615. http://dx.doi.org/10.1093/ jac/dks084.
11. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. The insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55:3022-3024. http://dx.doi.org/10.1128/AAC.01732-10.
12. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
13. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly- -1,6-Nacetylglucosamine. Antimicrob. Agents Chemother. 56:59-69. http://dx.doi.org/10.1128/AAC.05191-11.
14. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.
15. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55:3370-3379. http://dx.doi.org/10.1128/AAC.00079-11.
16. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. 2011. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of Lipid A. Antimicrob. Agents Chemother. 55: 3743-3751. http://dx.doi.org/10.1128/ AAC.00256-11.
17. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. 2011. Efficacy and safety of tigecycline for the treatment of infectious diseases: A metaanalysis. Lancet Infect. Dis. 11:834-844. http://dx.doi.org/10.1016/S1473-3099(11)70177-3.
18. López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y, Fernández-Reyes M, Rivas L, Pachón J. 2011. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J. Infect. Dis. 203:545-548. http://dx.doi.org/10.1093/ infdis/jiq086.
19. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. 2011. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: A case report from Spain. J. Infect. Dis. 204:1147-1148. http://dx.doi.org/10.1093/infdis/jir476.
20. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. 2011. Acinetobacter baumannii resistant to colistin with impaired virulence: A case report from France. J. Infect. Dis. 204:1146-1147. http://dx.doi.org/10.1093 /infdis/jir475.
21. Bou G, Martínez-Beltrán J. 2000. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 44:428-432. http://dx.doi.org/10.1128/AAC.44.2.428-432.2000.
22. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 17th informational supplement M07-A9. CLSI, Wayne, PA.
23. Andrews JM. 2001. Determination of minimum inhibitory concentrations. 2001. J. Antimicrob. Chemother. 48(Suppl):5-16. http://www.ncbi.nlm.nih.gov/ pubmed/11420333.
24. Sulston J, Hodgkin J. 1988. Methods, p 587-606. In Wood WB (ed), The nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
25. Aranda J, Garrido ME, Fittipaldi N, Cortés P, Llagostera M, Gottschalk M, Barbé J. 2010. The cation-uptake regulators AdcR and Fur are necessary for full virulence of Streptococcus suis. Vet. Microbiol. 144:246-249. http://dx.doi.org/10.1016/j.vetmic.2009.12.037.
26. McConnell MJ, Domínguez-Herrera J, Smani Y, López-Rojas R, Docobo-Pérez F, Pachón J. 2011. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect. Immun. 79:518-526. http://dx.doi.org/10.1128/IAI.00741-10.
27. Beceiro A, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Bou G, Pachón J, Spanish Network for Research in Infectious Diseases (REIPI). 2009. In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Antimicrob. Agents Chemother. 53: 4298-4304. http://dx.doi.org/10.1128/AAC.00320-09.
28. Motegi M, Takagi Y, Yonezawa H, Hanada N, Terajima J, Watanabe H, Senpuku H. 2006. Assessment of genes associated with Streptococcus mutans biofilm morphology. Appl. Environ. Microbiol. 72:6277-6287. http: //dx.doi.org/10.1128/ AEM.00614-06.
29. Lindbäck T, Rottenberg ME, Roche SM, Rørvik LM. 2010. The ability to enter into an avirulent viable but non-culturable (VBNC) form is widespread among Listeria monocytogenes isolates from salmon, patients and environment. Vet. Res. 41:8. http://dx.doi.org/10.1051/vetres/2009056.
30. Garcia-Sureda L, Domenech-Sanchez A, Barbier M, Juan C, Gasco J, Alberti S. 2011. OmpK26, a novel porin associated with carbapenem resistance in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55: 4742-4747. http://dx.doi.org/10.1128/AAC.00309-11.
31. Fernandez A, Perez A, Ayala JA, Mallo S, Rumbo-Feal S, Tomas M, Poza M, Bou G. 2012. Expression of OXA-type and SFO-1 betalactamases induces changes in peptidoglycan composition and affects bacterial fitness. Antimicrob. Agents Chemother. 56:1877-1884. http://dx.doi.org/10.1128/AAC.05402-11.
32. Feinbaum RL, Urbach JM, Liberati NT, Djonovic S, Adonizio A, Carvunis AR, Ausubel FM. 2012. Genome-wide identification of Pseudomonas aeruginosa virulence-related genes using a Caenorhabditis elegans infection model. PLoS Pathog. 8:e1002813. http://dx.doi.org/10.1371/journal.ppat.1002813.
33. Tan MW, Rahme LG, Sternberg JA, Tompkins RG, Ausubel FM. 1999. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc. Natl. Acad. Sci. U. S. A. 96:2408- 2413. http://dx.doi.org/10.1073/pnas.96.5.2408.
34. Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, Snyder M. 2007. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev. 21:601-614. http://dx.doi.org/10.1101/gad.1510307.
35. Tan MW, Mahajan-Miklos S, Ausubel FM. 1999. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 96:715-720. http://dx.doi.org/10. 1073/pnas.96.2.715.
36. Beceiro A, Tomás M, Bou G. 2013. Antimicrobial resistance and virulence: A successful or deleterious association in the bacterial world? Clin. Microbiol. Rev. 26:185-230. http://dx.doi.org/10.1128/CMR.00059-12.
37. Mahajan-Miklos S, Tan MW, Rahme LG, Ausubel FM. 1999. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa- Caenorhabditis elegans pathogenesis model. Cell 96:47-56. http://dx.doi.org/10. 1016/S0092-8674(00)80958-7.
38. Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, Ko KS. 2009. Independent emergence of colistin-resistant Acinetobacter spp. Isolates from Korea. Diagn. Microbiol. Infect. Dis. 64:43-51. http://dx.doi.org/10.1016/j. diagmicrobio.2009.01.012.
39. Yoon EJ, McGann P, Lesho E, Waterman P, Clifford R, Courvalin P, Grillot-Courvalin C. 2013. Biological cost of colistin-resistance in clinical isolates of Acinetobacter baumannii. 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany.
40. Park YK, Choi JY, Shin D, Ko KS. 2011. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents 37:525- 530. http://dx.doi.org/10.1016/j.ijantimicag.2011.02.008.
41. Soon RL, Nation RL, Harper M, Adler B, Boyce JD, Tan CH, Li J, Larson I. 2011. Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy. Int. J. Antimicrob. Agents 38:493-501. http://dx.doi.org/10.1016/j.ijantimicag.2011.07. 014.
42. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C, Pachón J, Andreu D, Rivas L. 2009. The cost of resistance to colistin in Acinetobacter baumannii: A proteomic perspective. Proteomics 9:1632-1645. http://dx.doi.org/10.1002/pmic.200800434.
43. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3:e00312-12. http://dx.doi.org/10.1128/mBio.00312-12.
44. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus- Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. 2013. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J. Infect. Dis. 7:1142-1151. http://dx.doi.org /10.1093/infdis/jit293.
45. López-Rojas R, McConnell MJ, Jiménez-Mejías ME, Domínguez- Herrera J, Fernández-Cuenca F, Pachón J. 2013. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob. Agents Chemother. 57:4587-4589. http://dx.doi.org/10.1128/AAC.00543-13.
46. Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R. 2010. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:3998-3999. http://dx.doi.org/10. 1128/AAC.00264-10.